AIM

Abcam: Appointment of Vice President of Investor Relations

Retrieved on: 
Monday, June 27, 2022
AIM, Biology, Research, Biomarker, ADSS, Company, London, Industry, Disease, ABC, Nasdaq, London Stock Exchange, Learning, American depositary receipt, Antibody, PerkinElmer, Health, Investor relations, TIAA, Management, Abcam

CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.

Key Points: 
  • CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.
  • He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years.
  • Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer.
  • His deep industry experience, significant investor relations expertise, and strong institutional investor and research analyst relationships are a major step forward for us.

Abcam: Appointment of Vice President of Investor Relations

Retrieved on: 
Monday, June 27, 2022
AIM, Biology, Research, Biomarker, ADSS, Company, London, Industry, Disease, ABC, Nasdaq, London Stock Exchange, Learning, American depositary receipt, Antibody, PerkinElmer, Health, Investor relations, TIAA, Management, Abcam

CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.

Key Points: 
  • CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.
  • He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years.
  • Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer.
  • His deep industry experience, significant investor relations expertise, and strong institutional investor and research analyst relationships are a major step forward for us.

Groundbreaking Digital Approach in Partnership Between East Kent Hospitals and Digital Pathology Company Source LDPath Helps Cut Pathology Waiting Times

Retrieved on: 
Monday, June 27, 2022
Diagnosis, Review, Health, AIM, Pathology, Patient, Trust, East Kent Hospitals University NHS Foundation Trust, William Harvey Hospital, Glass, NHS foundation trust, Population, Cancer, London, Maidstone, Marie Cassidy, Precision medicine, London Stock Exchange, Partnership, NHS, SBI, Queen Elizabeth The Queen Mother Hospital, Source, Hospital, Online shopping, Health insurance, Medical imaging, Genomics

NOTTINGHAM, England, June 27, 2022 /PRNewswire/ -- An innovative partnership between East Kent Hospitals and digital pathology company Source LDPath, a part of SourceBio International plc, is helping to reduce pathology waiting times and improve patient care.

Key Points: 
  • NOTTINGHAM, England, June 27, 2022 /PRNewswire/ -- An innovative partnership between East Kent Hospitals and digital pathology company Source LDPath, a part of SourceBio International plc, is helping to reduce pathology waiting times and improve patient care.
  • The Trust has teamed up with Source LDPath to send digital images of slides to their network of pathologists so they can be checked for a range of diseases, including cancer.
  • More than 4,000 cases have been examined digitally since the partnership launched in December 2021.
  • "This innovative approach helps to minimise delays, which means patients can start treatment earlier and have better outcomes in many cases.

The Craneware Group Unveils Trisus Chargemaster Solution and New Branding at HFMA Annual Conference

Retrieved on: 
Sunday, June 26, 2022
Efficiency, KLAS, AIM, HFMA, CEO, HITRUST, CDM, Intelligence, Dro Trisu Ramsha, Health care, OPPS, Software as a service, Compliance, Revenue cycle management, Certification, Healthcare Financial Management Association, Unlock, Solution, Pop 2 (mixtape), Conference, Calculator

ATLANTA, June 26, 2022 /PRNewswire/ -- The Craneware Group (AIM: CRW.L), the healthcare market leader in automated value cycle solutions, announced today the unveiling of its Trisus Chargemaster application at the Healthcare Financial Management Association (HFMA) Annual Conference in Denver.

Key Points: 
  • ATLANTA, June 26, 2022 /PRNewswire/ -- The Craneware Group (AIM: CRW.L), the healthcare market leader in automated value cycle solutions, announced today the unveiling of its Trisus Chargemaster application at the Healthcare Financial Management Association (HFMA) Annual Conference in Denver.
  • Trisus Chargemaster is an evolution of the award-winning Chargemaster Toolkit, the industry's first automated chargemaster management solution.
  • "Trisus Chargemaster represents a transformational approach to CDM management, with easy-to-use functionality that increases efficiency, scalability, performance to facilitate optimal collaboration between operational, financial and clinical teams," said Keith Neilson, CEO of The Craneware Group.
  • Visitors to The Craneware Group booth will experience a new tri-color brand design and demonstrations of the exponential power of the company's Trisus platform and 340B solutions.

Update on Suspension of Trading

Retrieved on: 
Friday, June 24, 2022
General Health, Pharmaceutical, Health, MSD, FDA, AIM, Pharma, Patient, Piper LBP, Achievement, DDDD, Pembrolizumab, Institutional review board, CNS, Cancer, Company, Disease, Irritable bowel syndrome, IBS, Pancreatic cancer, Bacteria, Merck, Merck & Co., Facility, Board, Avelumab, China Biologic Products, Squamous cell carcinoma, Vaccine, Asthma, Pharmaceutical industry

Subsequent to the suspension, the Board was informed that Oxford had today instructed that the Company be placed into administration, in accordance with the terms of the Facility.

Key Points: 
  • Subsequent to the suspension, the Board was informed that Oxford had today instructed that the Company be placed into administration, in accordance with the terms of the Facility.
  • Accordingly, James Clark and David Pike of Interpath Advisory have been appointed as joint administrators to 4D pharma plc (the Joint Administrators).
  • 4D pharma has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
  • A Phase I study of MRx0005 and MRx0029 in patients with Parkinsons disease is expected to commence in 2022.

Advisors Asset Management Appoints Bill Wendel Head of Institutional & Alternatives

Retrieved on: 
Thursday, June 23, 2022
Solution, Industry, UIT, Senior, Technology, LP, CIO, Spinal muscular atrophies, Fordham University, ETF, DNA, Marketing, Investment, AIM, SEC, Asset, AAM, BNY Mellon, Income, Face, JPMorgan Chase, Financial adviser

MONUMENT, Colo., June 23, 2022 /PRNewswire/ -- Advisors Asset Management (AAM), a leading investment solutions provider, announced today that Bill Wendel has joined the firm as its Managing Director, Head of Institutional & Alternatives, reporting directly to AAM President & CIO, Cliff Corso. Wendel will spearhead the firm's efforts to design and deliver a number of advisor-friendly products and solutions for alternative investments.

Key Points: 
  • Wendel will spearhead the firm's efforts to design and deliver a number of advisor-friendly products and solutions for alternative investments.
  • "One of the biggest challenges that advisors face in today's market is the search for income and diversification," said Bill Wendel, Managing Director, Head of Institutional & Alternatives at AAM.
  • Our goal is to partner with industry-leading, institutional managers with focused expertise across select income oriented alternative asset classes.
  • Advisors Asset Management, Inc. (AAM) is a SEC-registered investment advisor and member FINRA/SIPC.

AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

Retrieved on: 
Tuesday, June 21, 2022
Cancer, Erasmus MC, Therapy, COVID-19, PSLRA, Medi-Cal Access Program, EAP, Company, North Brunswick, New Jersey, Research, Pancreatic cancer, Private Securities Litigation Reform Act, Disease, Immune system, AIM, New Jersey Economic Development Authority, ME/CFS, Patient, Inspectorate, American, Degenerative disease, Rintatolimod, Chronic fatigue syndrome, NYSE, GLOBE, Lists of diseases, Vaccine, Pharmaceutical industry

AIM Chief Executive Officer Thomas K. Equels commented, The AIM team is pleased to join a number of thriving, prestigious life sciences companies at the NJBC.

Key Points: 
  • AIM Chief Executive Officer Thomas K. Equels commented, The AIM team is pleased to join a number of thriving, prestigious life sciences companies at the NJBC.
  • This state-of-the-art facility will help us to continue to advance our research and development of Ampligen to treat multiple types of cancers, immune disorders, and viral diseases.
  • We have made a significant investment in new equipment for this facility and believe that this space will enhance our future development progress.
  • AIM ImmunoTech Inc. is an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

Tremor International Enhances Partnership with VIDAA through Strategic Investment

Retrieved on: 
Tuesday, June 21, 2022
Advertising, Tremor International, NEW, Television, London Stock Exchange, Smart TV, Toshiba, London, Technology, Hisense, CEO, OS, ACR, Ecosystem, DSPS, AIM, NASDAQ, SSP, Tremor, Partnership, News Corp, GLOBE, Original equipment manufacturer, CTV, OEM, Connected, Video game console, Video game, Video, Investment, Unruly Heroes

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Tremor International Ltd. (AIM/NASDAQ: TRMR) (“Tremor” or the “Company”), a global leader in video, data, and Connected TV (“CTV”) advertising, offering an end-to-end technology platform that enables advertisers to optimize their campaigns and media partners to maximize yield on their digital advertising inventory, today announced that it has entered into a definitive agreement to make a strategic $25 million investment in VIDAA (the “Investment”), a smart TV operating system and streaming platform, and a subsidiary of Hisense Co., Ltd (“Hisense”), preinstalled on a majority of TVs manufactured by Hisense including TVs with the Toshiba brand, and also integrated into dozens of premium original equipment manufacturers (“OEMs”). The Investment is expected to close in the third quarter of 2022, subject to the satisfaction of customary closing conditions. Tremor intends to fund the investment utilizing existing cash resources.

Key Points: 
  • The Investment is expected to close in the third quarter of 2022, subject to the satisfaction of customary closing conditions.
  • Guy Edri, President, VIDAA said: In Tremor International, we have a team stacked with CTV experts and a global solution that empowers us to get the most out of our strategy.
  • Ofer Druker, CEO, Tremor International said: Our strategic partnership and mutual vision with VIDAA is rare in the ad tech marketplace, and we believe it provides Tremor with cutting-edge capabilities in the CTV ecosystem.
  • Tremor International is a global company offering an end-to-end technology advertising platform, operating across three core capabilities - Video, Data and CTV.

Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Retrieved on: 
Tuesday, June 21, 2022
Biotechnology, Health, Oncology, ICIS, Society, LinkedIn, Macmillan Cancer Support, Disease, Cancer research, AIM, 3D, IHC, ASCO, Cancer Research UK, Merck Serono, Prevalence, Therapy, Technology, Real-time, Biotechnology, Laboratory developed test, Physician, Twitter, ICI, OBD, Mayo Clinic, Genomics, London Stock Exchange, London, ESMO, Mitsubishi Tanabe Pharma, NHS, Biomarker, Lung cancer, Patient, Architecture, Systems biology, Multimedia, PD-L1, Melanoma, Immunotherapy, LDT, CST, Checkpoint, Oncology, Company, Precision medicine, Cancer, Research, Massachusetts General Hospital, Prognosis, Pfizer, Roche, NPV, Oxford University Hospitals NHS Foundation Trust, Genome, Biogen, MedRxiv, CIRT, Pharmaceutical industry, Medical imaging, MD, Genentech

The CiRT will initially be available as an LDT to private healthcare providers in the UK.

Key Points: 
  • The CiRT will initially be available as an LDT to private healthcare providers in the UK.
  • It is estimated that around 350,000 people are diagnosed each year, amounting to over 1,000 new cases per day ( Cancer Research UK ).
  • EpiSwitch CiRT has the potential to address this testing issue with the introduction of a specific and accurate IO [immuno-oncology] response test.
  • Its flagship product is EpiSwitch CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

Proactive news headlines including Future Metals, Armada Metals, Recce Pharmaceuticals and Race Oncology

Retrieved on: 
Tuesday, June 21, 2022
Lithium, WKT, El Palmar, RCE, Gold, MRE, RTX, FEX, Lac Minerals Ltd v International Corona Resources Ltd, Safety, STM, Research, ASX, JORC, OTC, Palladium, RAC, Cancer research, MGV, Program, AIM, News, Acquisition, GTR, CXO, RC, Proactivity, Blackcraig Hill, Platinum, Male, GLOBE, Nickel, Rare-earth element, Mining, Uranium, Norsemen, Callisto

Click here

Key Points: 
  • Click here
    Armada Metals Ltd (ASX:AMM) has intersected magmatic nickel-copper sulphides during phase one diamond drilling at the Nyanga Project in Gabon.
  • Click here
    Race Oncology Ltd (ASX:RAC) has seen two of its peer-reviewed abstracts published in the prestigious scientific journal Cancer Research with shares trading higher as a result.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]